These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 22492246)
1. Pre- and post-operative plasma glial fibrillary acidic protein levels in patients with newly diagnosed gliomas. Husain H; Savage W; Grossman SA; Ye X; Burger PC; Everett A; Bettegowda C; Diaz LA; Blair C; Romans KE; Holdhoff M J Neurooncol; 2012 Aug; 109(1):123-7. PubMed ID: 22492246 [TBL] [Abstract][Full Text] [Related]
2. Pre- and early postoperative GFAP serum levels in glioma and brain metastases. Baumgarten P; Quick-Weller J; Gessler F; Wagner M; Tichy J; Forster MT; Foerch C; Seifert V; Mittelbronn M; Senft C J Neurooncol; 2018 Sep; 139(3):541-546. PubMed ID: 29797180 [TBL] [Abstract][Full Text] [Related]
3. Serum levels of glial fibrillary acidic protein correlate to tumour volume of high-grade gliomas. Brommeland T; Rosengren L; Fridlund S; Hennig R; Isaksen V Acta Neurol Scand; 2007 Dec; 116(6):380-4. PubMed ID: 17986096 [TBL] [Abstract][Full Text] [Related]
4. Serum levels of GFAP and EGFR in primary and recurrent high-grade gliomas: correlation to tumor volume, molecular markers, and progression-free survival. Kiviniemi A; Gardberg M; Frantzén J; Parkkola R; Vuorinen V; Pesola M; Minn H J Neurooncol; 2015 Sep; 124(2):237-45. PubMed ID: 26033547 [TBL] [Abstract][Full Text] [Related]
5. Diagnostic and prognostic value of preoperative combined GFAP, IGFBP-2, and YKL-40 plasma levels in patients with glioblastoma. Gállego Pérez-Larraya J; Paris S; Idbaih A; Dehais C; Laigle-Donadey F; Navarro S; Capelle L; Mokhtari K; Marie Y; Sanson M; Hoang-Xuan K; Delattre JY; Mallet A Cancer; 2014 Dec; 120(24):3972-80. PubMed ID: 25139333 [TBL] [Abstract][Full Text] [Related]
6. Serum concentrations of glial fibrillary acidic protein (GFAP) do not indicate tumor recurrence in patients with glioblastoma. Vietheer JM; Rieger J; Wagner M; Senft C; Tichy J; Foerch C J Neurooncol; 2017 Oct; 135(1):193-199. PubMed ID: 28717884 [TBL] [Abstract][Full Text] [Related]
8. Pathologic Findings and Clinical Course of Midline Paraventricular Gliomas Diagnosed Using a Neuroendoscope. Fukami S; Nakajima N; Okada H; Akimoto J; Miki T; Fukuhara H; Shishido-Hara Y; Nagao T; Tsuda M; Kohno M World Neurosurg; 2018 Jun; 114():e366-e377. PubMed ID: 29530692 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of eight plasma proteins as candidate blood-based biomarkers for malignant gliomas. Lange RP; Everett A; Dulloor P; Korley FK; Bettegowda C; Blair C; Grossman SA; Holdhoff M Cancer Invest; 2014 Oct; 32(8):423-9. PubMed ID: 25019213 [TBL] [Abstract][Full Text] [Related]
10. Plasma miR-454-3p as a potential prognostic indicator in human glioma. Shao N; Wang L; Xue L; Wang R; Lan Q Neurol Sci; 2015 Feb; 36(2):309-13. PubMed ID: 25190548 [TBL] [Abstract][Full Text] [Related]
11. Serum GFAP autoantibody as an ELISA-detectable glioma marker. Wei P; Zhang W; Yang LS; Zhang HS; Xu XE; Jiang YH; Huang FP; Shi Q Tumour Biol; 2013 Aug; 34(4):2283-92. PubMed ID: 23589055 [TBL] [Abstract][Full Text] [Related]
12. Serum lactate levels are associated with glioma malignancy grade. Branco M; Linhares P; Carvalho B; Santos P; Costa BM; Vaz R Clin Neurol Neurosurg; 2019 Nov; 186():105546. PubMed ID: 31605893 [TBL] [Abstract][Full Text] [Related]
13. A microRNA signature from serum exosomes of patients with glioma as complementary diagnostic biomarker. Santangelo A; Imbrucè P; Gardenghi B; Belli L; Agushi R; Tamanini A; Munari S; Bossi AM; Scambi I; Benati D; Mariotti R; Di Gennaro G; Sbarbati A; Eccher A; Ricciardi GK; Ciceri EM; Sala F; Pinna G; Lippi G; Cabrini G; Dechecchi MC J Neurooncol; 2018 Jan; 136(1):51-62. PubMed ID: 29076001 [TBL] [Abstract][Full Text] [Related]
14. Prospective evaluation of serum glial fibrillary acidic protein (GFAP) as a diagnostic marker for glioblastoma. Tichy J; Spechtmeyer S; Mittelbronn M; Hattingen E; Rieger J; Senft C; Foerch C J Neurooncol; 2016 Jan; 126(2):361-9. PubMed ID: 26518540 [TBL] [Abstract][Full Text] [Related]
15. The prognostic value of clinical factors and cancer stem cell-related markers in gliomas. Dahlrot RH Dan Med J; 2014 Oct; 61(10):B4944. PubMed ID: 25283629 [TBL] [Abstract][Full Text] [Related]
16. Plasma miR-122 as a potential diagnostic and prognostic indicator in human glioma. Tang Y; Zhao S; Wang J; Li D; Ren Q; Tang Y Neurol Sci; 2017 Jun; 38(6):1087-1092. PubMed ID: 28367610 [TBL] [Abstract][Full Text] [Related]
17. Altered galectin-1 serum levels in patients diagnosed with high-grade glioma. Verschuere T; Van Woensel M; Fieuws S; Lefranc F; Mathieu V; Kiss R; Van Gool SW; De Vleeschouwer S J Neurooncol; 2013 Oct; 115(1):9-17. PubMed ID: 23824536 [TBL] [Abstract][Full Text] [Related]
19. Serum glial fibrillary acidic protein is a predictor of brain metastases in patients with metastatic breast cancer. Darlix A; Hirtz C; Mollevi C; Ginestet N; Tiers L; Jacot W; Lehmann S Int J Cancer; 2021 Oct; 149(8):1605-1618. PubMed ID: 34196964 [TBL] [Abstract][Full Text] [Related]
20. Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas. Lin Y; Jiang T; Zhou K; Xu L; Chen B; Li G; Qiu X; Jiang T; Zhang W; Song SW Neuro Oncol; 2009 Oct; 11(5):468-76. PubMed ID: 19164435 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]